Jan. 11, 2020: Issue #1024 TOP STORIES - Diabetes News & Research |
|
Letter from the Editor
Jan. 11, 2020
 I recently had our intern Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy, take a look at the latest information comparing DPP-4 inhibitors with SGLT-2 inhibitors. I had asked her to see if there was enough evidence to cause you, our readers, to choose one over the other.
She delivered on that request with a comparison article and then went the extra step: that not only did they do a better job for cardiovascular patients, they actually saved health plans and patients money.
We have moved our newsletters to a new server in order to provide you with a more robust experience. Please make sure to add news@mail.diabetesincontrol.com to your contacts/whitelist so you don’t miss a single issue.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
|
Doctor's Option lab test products include rapid tests and CLIA certified fingerstick lab tests.
Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.
Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.
Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.
Visit Doctor's Option |
|
|
|
|
Newsflash: Novo Nordisk Offers Free Insulin to U.S. Patients
Novo Nordisk is offering free, one-time supply of insulin to people in immediate need. Novo said patients with a prescription can get a free, one-time supply of up to three vials or two packs of pens of its insulin. They also stated that patients can buy three vials or two packs of pens of its analog insulins for $99. More info |
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| Did You Know: We May be Unprepared for Coming Diabetes Epidemic
If we were to do A1c tests on the entire US population today, we would find that there are about 100 million people with prediabetes, according to the CDC. Per the predictions of the researchers, half the US population will have prediabetes within ten years, and in every single state, no fewer than 35% of adults will have a body mass index of at least 30, the threshold that defines obesity.
Body mass index, a measure of fatness based on a person’s height and weight, has its limitations as a predictor of personal health. But in large populations where rates of obesity are higher, people tend to be sicker. Even worse: as the nation continues to accumulate fat, nearly 1 in 4 U.S. adults will have “severe obesity.” Defined as having a BMI of 40 or above, severe obesity will become about as common in 2030 as regular obesity was in the 1990s. Where Americans had obesity, the generation behind them is expected to develop severe obesity — and their risk of joint and back problems, diabetes, cardiovascular disease, certain cancers, and early death will be even higher. Studies have shown that having prediabetes and diabetes can increase the risk of heart attacks, strokes, and death. In a current study, they found that there was a twofold higher unadjusted risk for CVD in people with prediabetes While HbA1c adds to cardiovascular risk prediction, those with prediabetes should have their conventional cardiovascular risk factors appropriately measured and managed. Providing an A1c for every patient is a way to inform and motivate patients to better health.
The findings were published in last week’s New England Journal of Medicine.
Diabetes Care 2019 Dec; dc191683. https://doi.org/10.2337/dc19-1683 |
|
|
| Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:
Andrew Daoud, PharmD Candidate, Florida A&M University
Joel John, Pharm.D. Candidate, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences
Emma Kammerer, L|E|C|O|M Bradenton School of Pharmacy, PharmD Candidate
Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy |
|
|
|
|
|
|  About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| ©2019 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: |
|
|
|
|
|
|
